DEXTENZA
Total Payments
$8.8M
Transactions
12,673
Doctors
4,168
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $521,647 | 3,726 | 1,751 |
| 2023 | $735,709 | 3,475 | 1,597 |
| 2022 | $1.7M | 1,834 | 1,134 |
| 2021 | $2.2M | 2,030 | 1,109 |
| 2020 | $2.9M | 1,372 | 757 |
| 2019 | $650,452 | 236 | 117 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.9M | 476 | 78.7% |
| Grant | $420,000 | 3 | 4.8% |
| Consulting Fee | $410,736 | 284 | 4.7% |
| Food and Beverage | $385,717 | 11,527 | 4.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $274,445 | 118 | 3.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $175,767 | 63 | 2.0% |
| Honoraria | $154,460 | 73 | 1.8% |
| Travel and Lodging | $41,231 | 86 | 0.5% |
| Long term medical supply or device loan | $6,635 | 32 | 0.1% |
| Education | $3,197 | 11 | 0.0% |
Payments by Type
Research
$6.9M
476 transactions
General
$1.9M
12,197 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| The SPENCER Study | Ocular Therapeutix, Inc. | $443,625 | 0 |
| A Prospective Multicenter Open Label Study to Evaluate the Safety Tolerability and Efficacy of OTX TIC Implant in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension | Ocular Therapeutix, Inc. | $386,762 | 0 |
| In Clinic Optometrist Insertion of DEXTENZA Prior to Cataract Surgery | Ocular Therapeutix, Inc. | $353,184 | 0 |
| Assessing the efficacy and safety of DEXTENZA, sustained release dexamtheasone 0.4mg insert, when placed within the lower and upper eye lid canaliculus in conjunction with topical prednisolone acetate 1% for the treatment of pain, and inflammation following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1% monotherapy | Ocular Therapeutix, Inc. | $282,105 | 0 |
| A Prospective, Multicenter, Open Label Extension Study to Evaluate the Long Term Safety of OTX-TP | Ocular Therapeutix, Inc. | $256,921 | 0 |
| Assessing the efficacy and safey of DEXTENZA, Sustained release dexamethasone 0.4 mg insert, when placed within the lower eye lid canaliculus compared to loteprednol suspension for the treatment of episodic of dry eye | Ocular Therapeutix, Inc. | $231,580 | 0 |
| DEXTENZA Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis | Ocular Therapeutix, Inc. | $224,861 | 0 |
| Open Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects with Primary Open-Angle Glaucoma or Ocular Hypertension | Ocular Therapeutix, Inc. | $201,506 | 0 |
| Intracanalicular Dexamethasone used in conjunction with iLUX for the treatment of meibomian gland dysfunction in patients with evaporative dry eye disease and evidence of clinically significant inflammation | Ocular Therapeutix, Inc. | $191,945 | 0 |
| The AtLAS Study | Ocular Therapeutix, Inc. | $167,630 | 0 |
| A Randomized, Parallel-Arm, Active Control, Multi-Center Study Assessing the Safety And Efficacy Of Dextenza for the Treatment Of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract | Ocular Therapeutix, Inc. | $159,605 | 0 |
| Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza) in the Management of Clinically Significant Dry Eye | Ocular Therapeutix, Inc. | $155,056 | 0 |
| A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3a Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension | Ocular Therapeutix, Inc. | $143,861 | 0 |
| The RESTORE Study | Ocular Therapeutix, Inc. | $139,430 | 0 |
| The PRIME Study | Ocular Therapeutix, Inc. | $137,780 | 0 |
| Randomized, controlled treatment with an intracanaliuclar dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHTN) | Ocular Therapeutix, Inc. | $137,200 | 0 |
| The NAVY Study (DEX in the DOD) | Ocular Therapeutix, Inc. | $125,000 | 0 |
| The pharmacokinetics of aqueous dexamethasone and the inflammatory cytokine response after treatment with a dexamethasone intracanalicular insert | Ocular Therapeutix, Inc. | $124,680 | 0 |
| The SITE Study | Ocular Therapeutix, Inc. | $122,959 | 1 |
| A Randomized Multi center Double masked Vehicle controlled phase 1 phase 2 Study to Evaluate the Safety Tolerability and Efficacy of OTX CSI for Intracanalicular Use for the Treatment of Subjects With Dry Eye Disease | Ocular Therapeutix, Inc. | $121,235 | 0 |
Top Doctors Receiving Payments for DEXTENZA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $6.8M | 473 |
| , MD | Ophthalmology | Los Angeles, CA | $253,723 | 33 |
| Jeffrey Heier | Ophthalmology | Boston, MA | $158,751 | 17 |
| , M.D | Ophthalmology | Bloomington, MN | $158,422 | 14 |
| , M.D | Ophthalmology | Wichita, KS | $111,596 | 5 |
| , MD | Ophthalmology | Wilkes Barre, PA | $63,500 | 15 |
| , M.D | Ophthalmology | Seguin, TX | $61,611 | 69 |
| , M.D | Ophthalmology | Morgantown, WV | $57,540 | 7 |
| Inder Singh | Ophthalmology | Racine, WI | $52,429 | 49 |
| , MD | Ophthalmology | Waco, TX | $41,044 | 50 |
| , M.D | Ophthalmology | Columbus, OH | $36,852 | 33 |
| , M.D | Internal Medicine | Staten Island, NY | $34,894 | 6 |
| , MD | Ophthalmology | Lake Villa, IL | $32,370 | 47 |
| , M.D | Ophthalmology | Overland Park, KS | $30,998 | 27 |
| , M.D | Ophthalmology | La Jolla, CA | $25,845 | 98 |
| Goldie Benz | Family | Liberty, MO | $25,803 | 36 |
| , MD | Ophthalmology | Springfield, IL | $25,293 | 30 |
| , MD | Ophthalmology | Smithtown, NY | $24,357 | 28 |
| , MD | Ophthalmology | Stanford, CA | $19,761 | 8 |
| , M.D | Ophthalmology | Laguna Hills, CA | $19,026 | 23 |
| , M.D | Ophthalmology | Oklahoma City, OK | $16,494 | 23 |
| , M.D | Ophthalmology | Durham, NC | $15,406 | 14 |
| , MD | Ophthalmology | Kansas City, MO | $15,192 | 38 |
| , M.D., P.A | Ophthalmology | Venice, FL | $14,856 | 25 |
| , M.D | Ophthalmology | Woodland Park, NJ | $14,846 | 45 |
Ad
Manufacturing Companies
- Ocular Therapeutix, Inc. $8.8M
Product Information
- Type Drug
- Total Payments $8.8M
- Total Doctors 4,168
- Transactions 12,673
About DEXTENZA
DEXTENZA is a drug associated with $8.8M in payments to 4,168 healthcare providers, recorded across 12,673 transactions in the CMS Open Payments database. The primary manufacturer is Ocular Therapeutix, Inc..
Payment data is available from 2019 to 2024. In 2024, $521,647 was paid across 3,726 transactions to 1,751 doctors.
The most common payment nature for DEXTENZA is "Unspecified" ($6.9M, 78.7% of total).
DEXTENZA is associated with 20 research studies, including "The SPENCER Study" ($443,625).